Literature DB >> 1383133

Interleukin-4 suppresses granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in stimulated human monocytes.

J A Hamilton1, G A Whitty, A K Royston, J Cebon, J E Layton.   

Abstract

Granulocyte colony-stimulating factor (G-CSF) was quantitated in the supernatants of lipopolysaccharide (LPS)-treated human monocytes by ELISA. Unlike previous reports, the lymphokines, interleukin-4 (IL-4) and interferon-gamma (IFN-gamma), were unable to induce the synthesis of G-CSF. Both IL-4 (> or = 10 pM) and the glucocorticoid, dexamethasone (10(-7) M), inhibited G-CSF production in the LPS-treated monocytes; in contrast, IFN-gamma had a weak potentiating effect on the LPS action. Changes in antigen expression were manifested at the level of messenger RNA (mRNA). Granulocyte-macrophage (GM)-CSF in the LPS-treated monocyte supernatants was also quantitated by ELISA but its levels were somewhat lower than for G-CSF; IL-4, dexamethasone and IFN-gamma had similar effects on GM-CSF levels as on G-CSF levels. The suppression of CSF production in the stimulated monocytes by IL-4 and glucocorticoid extends the list of monocyte cytokines whose levels can be down-regulated by these agents and suggests another potential anti-inflammatory and immunosuppressive function for IL-4.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383133      PMCID: PMC1421558     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  32 in total

1.  IL-4 inhibits the expression of IL-8 from stimulated human monocytes.

Authors:  T J Standiford; R M Strieter; S W Chensue; J Westwick; K Kasahara; S L Kunkel
Journal:  J Immunol       Date:  1990-09-01       Impact factor: 5.422

2.  IFN-gamma-induced L-arginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor-alpha.

Authors:  J A Langermans; M E Van der Hulst; P H Nibbering; P S Hiemstra; L Fransen; R Van Furth
Journal:  J Immunol       Date:  1992-01-15       Impact factor: 5.422

Review 3.  The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells.

Authors:  D Metcalf
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

4.  Augmentation of glucocorticoid action on human monocytes by interleukin-4.

Authors:  P H Hart; G A Whitty; D R Burgess; M Croatto; J A Hamilton
Journal:  Lymphokine Res       Date:  1990

5.  Interleukin-4 induces secretion of CSF for granulocytes and CSF for macrophages by peripheral blood monocytes.

Authors:  M Wieser; R Bonifer; W Oster; A Lindemann; R Mertelsmann; F Herrmann
Journal:  Blood       Date:  1989-04       Impact factor: 22.113

6.  Differential expression of M-CSF, G-CSF, and GM-CSF by human monocytes.

Authors:  M T Lee; K Kaushansky; P Ralph; M B Ladner
Journal:  J Leukoc Biol       Date:  1990-03       Impact factor: 4.962

7.  Stimulation of macrophage plasminogen activator activity by colony-stimulating factors.

Authors:  J A Hamilton; E R Stanley; A W Burgess; R K Shadduck
Journal:  J Cell Physiol       Date:  1980-06       Impact factor: 6.384

8.  Contrasting effects of interferon-gamma and interleukin-4 on the interleukin-6 activity of stimulated human monocytes.

Authors:  D L Cheung; P H Hart; G F Vitti; G A Whitty; J A Hamilton
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

9.  Activation of human monocytes by granulocyte-macrophage colony-stimulating factor: increased urokinase-type plasminogen activator activity.

Authors:  P H Hart; G F Vitti; D R Burgess; G A Whitty; K Royston; J A Hamilton
Journal:  Blood       Date:  1991-02-15       Impact factor: 22.113

10.  Independent regulation of M-CSF and G-CSF gene expression in human monocytes.

Authors:  E Vellenga; A Rambaldi; T J Ernst; D Ostapovicz; J D Griffin
Journal:  Blood       Date:  1988-06       Impact factor: 22.113

View more
  8 in total

1.  Induced expression of the new cytokine, activin A, in human monocytes: inhibition by glucocorticoids and retinoic acid.

Authors:  J Yu; L E Shao; N L Frigon; J Lofgren; R Schwall
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

2.  Epigenetic and transcriptional regulation of IL4-induced CCL17 production in human monocytes and murine macrophages.

Authors:  Amy T Hsu; Tanya J Lupancu; Ming-Chin Lee; Andrew J Fleetwood; Andrew D Cook; John A Hamilton; Adrian Achuthan
Journal:  J Biol Chem       Date:  2018-06-05       Impact factor: 5.157

3.  Differential regulation of tumour necrosis factor-alpha mRNA degradation in macrophages by interleukin-4 and interferon-gamma.

Authors:  K Suk; K L Erickson
Journal:  Immunology       Date:  1996-04       Impact factor: 7.397

4.  Granulocyte-macrophage colony-stimulating factor: involvement in control of Trypanosoma cruzi infection in mice.

Authors:  E Olivares Fontt; C Heirman; K Thielemans; B Vray
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

5.  IL-4 down-regulates IL-2-, IL-3-, and GM-CSF-induced cytokine gene expression in peripheral blood monocytes.

Authors:  F H Cluitmans; B H Esendam; J E Landegent; R Willemze; J H Falkenburg
Journal:  Ann Hematol       Date:  1994-06       Impact factor: 3.673

Review 6.  Current and future therapeutic options in the management of invasive aspergillosis.

Authors:  Suganthini Krishnan-Natesan; Pranatharthi H Chandrasekar
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer.

Authors:  Alexander M Aliper; Victoria P Frieden-Korovkina; Anton Buzdin; Sergey A Roumiantsev; Alex Zhavoronkov
Journal:  Oncotarget       Date:  2014-11-30

8.  Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production.

Authors:  A D'Andrea; X Ma; M Aste-Amezaga; C Paganin; G Trinchieri
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.